Meperizumab injection ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 44 | Wegener granulomatosis | 1 |
44. Wegener granulomatosis
Clinical trials : 98 / Drugs : 108 - (DrugBank : 28) / Drug target genes : 22 - Drug target pathways : 81
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05353179 (ClinicalTrials.gov) | June 2022 | 11/4/2022 | Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers | Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers | Granulomatosis With Polyangiitis;Hemophagocytic Syndrome | Drug: Meperizumab injection;Drug: NUCALA® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NULL | Not yet recruiting | 18 Years | 55 Years | Male | 88 | Early Phase 1 | China |